Gallic acid attenuates blood spinal cord barrier disruption by inhibiting Jmjd3 expression and activation after spinal cord injury

摘要

Utilizing DGMIF discovery platform we are developing a drug candidate for the treatment of attention deficit hyperactivity disor- der (ADHD). Our lead candidates showed comparable PK properties to centanafadine, and better efficacy in several mouse behavior model. Some of our research progress to generate preclinical can- didates will be presented.